PoC clinical study of ZPL-3893787 on pruritus and inflammation in atopic dermatitis

Ziarco Pharma Limited, of Canterbury, Kent is developing ZPL-3893787, a novel oral treatment for the itch and inflammation associated with chronic pruritus (CP) - defined as an undesirable condition that stimulates scratching, persisting for at least 6 weeks. It affects all ages, from young infants through to the elderly. CP can result in disturbed/lack of sleep, mood changes and a general increase in other illnesses for sufferers. ZPL-3893787 has been studied in over 50 healthly adult volunteers so far in two different countries. Financial help from the UK Government's Technology Strategy Board will allow Ziarco to test ZPL-3893787 for relieving itch and inflammation in atopic dermatitis (ezcema) patients. Itch and inflammation are present in many diseases, and if proved successful, ZPL-389 may have the chance to treat millions of patients worldwide, from the young through to the elderly.